This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the prescribing information.~ALTARGO is a trademark of the GlaxoSmithKline group of companies.
This is an open label, multi-centre, non-interventional post-marketing surveillance.